

Supplementary Table S1 Baseline characteristics of study patients at the time of primary diagnosis of ovarian cancer ($n = 49$)

Parameters	<i>n</i> (%)	Median	Range
Age		54	(45–60)
Duration from last platinum			
3–6 mo	28 (57%)		
< 3 mo	21 (43%)		
Median (range), mo		3.2	(2.1–4.6)
Histology			
Serous	39 (80%)		
Other ^a	10 (20%)		
Progression type^b			
Symptomatic	19 (39%)		
CA125 only	2 (4%)		
CA125 and imaging	28 (57%)		
Comorbidities			
Diabetes	8 (16.3%)		
Hypertension	7 (14.3%)		
ECOG performance status^b			
ECOG 0,1	13 (35%)		
ECOG 2,3	24 (65%)		
Number of previous lines of treatment			
1	38 (76%)		
≥2	11 (24%)		
Laboratory parameters			
Hemoglobin (g/L)		10.9	10–11.23
Total leukocyte count (/cmm)		8,025	6,585–9,183
Neutrophils (%)		68	58–76
Eosinophils (%)		2	1–5
Lymphocytes (%)		23	18–32
Monocytes (%)		4	3–5
Platelets(X1000/cmm)		336	292–410
Absolute monocyte count (/cmm)		290	252–410
Absolute lymphocyte count (/cmm)		1576	1411–2303
PLR		175	134–271
NLR		2.8	2–4
LMR		6.7	4–9

Abbreviations: ECOG, Eastern Cooperative Oncology Group; LMR, lymphocyte monocyte ratio; NLR, neutrophil lymphocyte ratio; PLR, platelet lymphocyte ratio.

^aMucinous ($n = 1$), endometrioid ($n = 4$), unknown ($n = 5$).

^bAt the time of platinum resistance; ECOG was available only for 37 patients.